IEL Peer Comparison

BSE: 524614

₹5.42

₹0.11 (2.07%)

As on 24-Sep-2026IST

Market cap

₹71 Cr

Revenue (TTM)

₹1 Cr

P/E Ratio

47.3

P/B Ratio

1.6

Div. Yield

0 %

Edit

	IEL	Parmax Pharma	Vasundhara Rasayan	Himadri Speciality	Deepak Nitrite
Market cap (₹ Cr)	71	94	51	34,071	21,849
Revenue (₹ Cr)	1	18	35	4,974	8,575
Net Profit (₹ Cr)	1.49	-1.19	5.90	804.14	783.41
Net Margin (%)	67.60	-5.82	15.67	15.54	9.08
RoE (%)	3.36	--	14.76	18.21	13.96
Price to Earnings	47.30	--	8.61	42.63	27.89
Price-To-Book	1.55	13.81	1.22	6.90	3.53

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	IEL	Parmax Pharma	Vasundhara Rasayan	Himadri Speciality	Deepak Nitrite
Operating Revenue	1.47	18.39	35.09	4,974.29	8,574.79
Total Income	2.21	20.51	37.68	5,175.21	8,624.11
Total Expenditure	0.36	20.90	28.94	3,969.25	7,243.44
EBITDA	1.11	-2.51	6.15	1,005.04	1,331.35
Depreciation	0.02	1.25	0.46	74.82	237.05
EBIT	1.09	-3.76	5.69	930.22	1,094.30
Interest	0.07	1.24	0.32	70.95	60.80
Other Income	0.74	2.12	2.59	200.92	49.32
Exceptional Items	0.00	0.00	0.00	0.00	-12.84
Profit before Tax	1.76	-2.88	7.97	1,060.19	1,069.98
Provision for Tax	0.27	-1.69	2.06	256.05	286.57
Profit after Tax	1.49	-1.19	5.90	804.14	783.41

Liabilities (₹ Cr)

	IEL	Parmax Pharma	Vasundhara Rasayan	Himadri Speciality	Deepak Nitrite
Shareholder's Funds	45.01	-6.15	40.88	4,706.68	5,836.83
Minority Interest	0.00	0.00	0.00	-4.97	-0.15
Non-Current Liabilities	1.46	11.52	0.41	308.16	1,532.66
Current Liabilities	0.62	22.68	6.60	1,236.15	1,278.74
Total Liabilities	46.92	18.75	43.07	5,100.22	7,706.02

Assets (₹ Cr)

	IEL	Parmax Pharma	Vasundhara Rasayan	Himadri Speciality	Deepak Nitrite
Non-Current Assets	12.06	11.38	2.36	3,202.99	5,145.91
Current Assets	35.04	16.68	45.34	2,823.52	3,069.38
Total Assets	46.92	18.75	43.07	5,100.22	7,706.02
Total Debt*	0.90	8.09	4.21	308.70	1,170.53
Net Current Assets	34.42	-6.00	38.74	1,587.37	1,790.64
Contingent Liabilities	0.41	--	1.09	50.60	0.53

Cashflow (₹ Cr)

	IEL	Parmax Pharma	Vasundhara Rasayan	Himadri Speciality	Deepak Nitrite
Cash From Operating Activities	2.11	-0.96	-5.83	446.86	624.70
Cash Flow from Investing Activities	-20.97	-0.70	0.46	-235.20	-1,491.33
Cash from Financing Activities	43.67	1.40	1.35	-271.49	806.16
Net Cash Inflow / Outflow	24.81	-0.26	-4.02	-59.84	-60.47

Ratios

Profitability Ratios

	IEL	Parmax Pharma	Vasundhara Rasayan	Himadri Speciality	Deepak Nitrite
ROCE (%)	2.44	-29.88	16.58	22.17	17.00
ROE (%)	3.36	0.00	14.76	18.21	13.96
ROA (%)	3.18	-5.10	12.98	14.67	9.55
EBIT Margin (%)	74.42	-20.44	16.22	18.70	12.76
Net Margin (%)	67.60	-5.82	15.67	15.54	9.08
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	IEL	Parmax Pharma	Vasundhara Rasayan	Himadri Speciality	Deepak Nitrite
Revenue Growth (%)	261.18	21.10	3.45	9.80	7.12
EBIT Growth (%)	228.86	-111.89	81.36	9.36	41.57
Net Profit Growth (%)	344.12	64.45	50.00	31.47	29.05
EPS Growth (%)	290.99	51.58	50.00	27.82	30.59
Book Value Growth (%)	3,563.74	-346.40	11.34	19.46	12.34

Valuation Ratios

	IEL	Parmax Pharma	Vasundhara Rasayan	Himadri Speciality	Deepak Nitrite
Price / Earnings	47.48	0.00	8.61	42.43	27.59
Price / Book Value	1.56	-5.86	1.22	6.90	3.54
Dividend Yield (%)	0.00	0.00	1.25	0.12	0.47
EV/EBITDA	41.84	80.88	7.74	33.81	17.22
Market Cap (₹ Cr)	61.28	15.80	73.37	20,933.97	27,044.64

Solvency Ratios

	IEL	Parmax Pharma	Vasundhara Rasayan	Himadri Speciality	Deepak Nitrite
Debt to Equity	0.02	-1.87	0.01	0.00	0.19
Short term debt to equity ratio	--	--	0.10	0.08	0.03
Current Ratio	56.24	0.74	6.87	2.28	2.40
Quick Ratio	56.24	0.39	6.64	1.67	1.73
Interest Coverage	24.78	-1.32	26.21	15.94	18.60

Operating Efficiency Ratios

	IEL	Parmax Pharma	Vasundhara Rasayan	Himadri Speciality	Deepak Nitrite
Debtors to sales (%)	25.24	17.20	21.25	14.00	17.56
Asset Turnover	0.03	0.79	0.77	0.91	1.05
Receivable days	49.30	20.01	55.72	50.98	56.28
Inventory Days	0.00	36.94	19.39	50.95	36.90
Payable days	74.11	149.20	45.04	46.50	33.64
Cash Conversion Cycle	-24.81	-92.25	30.08	55.43	59.53

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly